Data Insights

Polzastobart by Concentra Biosciences for Ovarian Cancer: Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Ovarian Cancer

Data Insights

Polzastobart by Concentra Biosciences for Solid Tumor: Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Solid Tumor

Data Insights

Polzastobart by Concentra Biosciences for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Polzastobart by Concentra Biosciences for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

Polzastobart by Concentra Biosciences for Pleomorphic Liposarcoma: Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Pleomorphic Liposarcoma

Data Insights

Polzastobart by Concentra Biosciences for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Metastatic Renal Cell Carcinoma

Data Insights

Polzastobart by Concentra Biosciences for Extrahepatic Bile Duct Cancer: Likelihood of Approval

Polzastobart is under clinical development by Concentra Biosciences and currently in Phase II for Extrahepatic Bile Duct Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Polzastobart in Extrahepatic Bile Duct Cancer